Alpha-GPC
CholinergicAlso known as: Alpha-glycerophosphocholine · L-Alpha glycerylphosphorylcholine · choline alfoscerate
A highly bioavailable choline compound that crosses the blood-brain barrier. Studied for cognitive enhancement, memory, and as a growth hormone secretagogue. Used in Europe for Alzheimer's treatment.
How expert claims hold up
9 of 18 claims assessed0 of 9 assessed claims supported or partially supported by published research
Evidence Summary
The available evidence for Alpha-GPC (L-α-glycerylphosphorylcholine) as a cognitive supplement is very limited based on the two studies reviewed. One was a randomized, double-blinded, placebo-controlled trial looking at choline intake from egg yolk in healthy middle-aged and older Japanese adults — a population and source that differ meaningfully from supplemental Alpha-GPC. The other was a review article focused primarily on regulatory approvals and market prospects rather than clinical outcomes. Both were rated as moderate quality, and neither directly tested Alpha-GPC supplementation in a way that allows confident conclusions about its effects on human cognition or performance. Key findings from the reviewed literature are narrow in scope. The egg yolk RCT examined whether dietary choline sources can influence plasma choline levels and cognitive function, which provides only indirect relevance to Alpha-GPC supplementation. The review article highlights that Alpha-GPC has received safety approvals in some regulatory contexts and is gaining commercial attention, but regulatory approval is not the same as demonstrated efficacy. Notably, all nine expert claims assessed about Alpha-GPC — spanning topics like cognitive enhancement, athletic performance, and neuroprotection — were flagged as having insufficient evidence, underscoring how thin the directly applicable human trial data is. There are significant gaps in the current evidence base. The studies available do not directly test Alpha-GPC supplements in controlled trials with clear cognitive or physical performance outcomes. Populations studied (middle-aged and older Japanese adults consuming egg yolk choline) may not generalize to younger adults or those using concentrated Alpha-GPC supplements. Dose-response relationships, optimal supplementation protocols, and long-term safety at supplemental doses remain poorly characterized by the literature provided. Consumers and clinicians should treat marketing claims about Alpha-GPC with caution until more rigorous, direct human trials are available.
Read full evidence summary →Top studies
Effects of egg yolk choline intake on cognitive functions and plasma choline levels in healthy middle-aged and older Japanese: a randomized double-blinded placebo-controlled parallel-group study.
Effects of egg yolk choline intake on cognitive functions and plasma choline levels in healthy middle-aged and older Japanese: a randomized double-blinded placebo-controlled parallel-group study.
Unlocking the potential of l-α-glycerylphosphorylcholine in the food industry: From safety approvals to market prospects.
Unlocking the potential of l-α-glycerylphosphorylcholine in the food industry: From safety approvals to market prospects.
Expert Mentions
All 18 mentions"there's a study suggesting that long-term high-dose choline supplementation may increase TMAO — trimethylamine N-oxide — production, which has been associated with cardiovascular risk. This is controversial and the magnitude of risk from supplemental doses isn't clear, but it's something to be aware of."
A study suggests that long-term high-dose choline supplementation may increase TMAO production, which has been associated with cardiovascular risk, though the magnitude of risk from supplemental doses is unclear.
"there's a study suggesting that long-term high-dose choline supplementation may increase TMAO — trimethylamine N-oxide — production, which has been associated with cardiovascular risk. This is controversial and the magnitude of risk from supplemental doses isn't clear, but it's something to be aware of."
A study suggests that long-term high-dose choline supplementation may increase TMAO production, which has been associated with cardiovascular risk, though the magnitude of risk from supplemental doses is unclear.
Neither of the two provided studies directly addresses the relationship between high-dose choline supplementation, TMAO production, and cardiovascular risk. The first study (PMID: 37340479) is an RCT examining egg yolk choline's effects on cognitive function in Japanese adults, and the second (PMID: 39898924) is a review focused on GPC in the food industry — neither reports on TMAO pathways or cardiovascular outcomes linked to supplemental choline. While the expert's claim about TMAO and cardiovascular risk is a plausible concern rooted in broader scientific literature, the specific studies provided here offer no data to support, contradict, or meaningfully evaluate that claim.
Key findings
- ·No studies in this review directly tested Alpha-GPC supplementation in a controlled human trial setting.
- ·A moderate-quality RCT examined dietary choline (from egg yolk) in middle-aged and older Japanese adults, providing only indirect relevance to Alpha-GPC use.
- ·A review article confirms Alpha-GPC has received some regulatory safety approvals, but this does not establish efficacy for any specific health claim.
Evidence gaps
- ·No direct RCTs testing Alpha-GPC supplements were included in this evidence set, leaving core efficacy claims unsubstantiated.
- ·The populations studied (older adults consuming food-based choline) may not reflect how most people use Alpha-GPC supplements, limiting generalizability.
- ·Long-term safety, effective dosing ranges, and comparative effectiveness of Alpha-GPC versus other choline sources remain unaddressed by the available literature.